cGMP-compliant production cell line for SARS-CoV-2 (COVID-19) Spike S1 Protein (RBD)
To support COVID-19 research and accelerate the rapid clinical development of your product candidate, trenzyme has developed a cGMP-compliant production cell line for the SARS-CoV-2 Spike S1 (RBD) protein based on the industry leading CHOvolution® CHO-K1 platform (Celonic AG).
After completion of the development process of the production cell line, the high quality research cell bank (RCB) can be transferred to a CDMO (Contract Development and Manufacturing Organization) of your choice for further process development, optimization and high level production.
Our cGMP- compliant Production Cell Line
Several high titer clones available
Full process documentation and certificates
Research Cell Bank (RCB), tested
more than 1 g/L at 1 L scale fed-batch based on CHOvolution® CHO-K1 cell line
Optimized production process, shake flask level (USP)
Optimized downstream purification process (DSP)
Easy transfer to your CDMO partner of choice
Preclinical grade material in lower gram amounts available
Commercially available media
Analytical methods including potency assay (hACE2 binding)
High Quality - Made in Germany
The domain of the SARS-CoV-2 Spike S1 (RBD) protein is the most important part of the viral spike protein and responsible for binding of the virus to the human receptor, the ACE-2 protein. Most patients recovered from COVID-19 have developed neutralizing antibodies against this protein, which has been proven by several animal studies. Therefore, it is the preferred target for vaccine development and neutralizing antibody production.